Tetrabenazine Drug Asset Due Diligence Report 2026

This Tetrabenazine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Tetrabenazine can convert its Small molecule drug profile and VMAT2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tetrabenazine (query alias: Tetrabenazine)
Modality / target	Small molecule drug; VMAT2; VMAT2 inhibitors
Highest global status	Approved
Originator	Hoffmann-La Roche Products Ltd.
Active developers	Bausch Health US LLC, H. Lundbeck A/S, UCB SA

The MCP disease footprint includes Chorea, Dyskinesia, Drug-Induced, Huntington Disease. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT04523935	Phase 4	Completed	131	Epidemiologic data (Age and sex).
CTRI/2024/11/077513	Phase 4	Not Yet Recruiting	30	Not disclosed
IRCT20240308061212N1	Phase 3	Recruiting	28	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Effect of Tetrabenazine on Stroop Interference in Huntington Disease

Phase 4; n=2; evaluation: not stated. Reported fields: Interference score OFF = -1.97 score on a scale ; -; -

Real-World Experiences with VMAT2 Inhibitors in Pediatric Hyperkinetic Movement Disorders (P7-6.020)

Not Applicable; n=340; evaluation: Positive. Reported fields: Adverse Event: side effects = most commonly drowsiness

Tetrabenazine and olanzapine in management of Huntington disease: comparative retrospective analysis of data from the worldwide observational study Enroll-HD (P2.008)

Phase 3; n=not disclosed; evaluation: Negative. Reported fields: Treatment period = 226.8 day ; Treatment period = 221.9 day

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tetrabenazine addresses Chorea, Dyskinesia, Drug-Induced, Huntington Disease. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2009-02-09	GTCR Completes the Sale of Ovation Pharmaceuticals to Lundbeck	Approved	US$900.0M stated total
2008-09-17	Biovail Acquires Prestwick Pharmaceuticals	Approved	US$100.0M stated total
2008-09-17	OVATION Pharmaceuticals, Inc. Acquires Rights to Commercialize Xenazine(R) (Tetrabenazine) in U.S. for Chorea Associated with Huntington's Disease	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Snedds based tetrabenazine formulation for the treatment of dystonia”. The milestone feed surfaced a patent-application signal described as “Methods of modulating tetrabenazine metabolites plasma levels using bupropion”. The milestone feed surfaced a patent-application signal described as “Tetrabenazine transdermal delivery device”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO